



final

Gynecologic Cancer InterGroup (GCIG)

Cervix Cancer Committee

Tuesday, Nov.10, 2015, 1:30p.m. – 3:30 p.m.

3F Room, Jikei University, Tokyo

Chair: Satoru Sagae Co-Chair: Brad Monk

Harmonization Liaisons: Hiltz (Ops), Reuss (Stats)

AGENDA

Please sign Attendance Forms

WELCOME & INTRODUCTIONS & COI declarations

Satoru Sagae

Approval of minutes: May 2015

Published/ In preparation

Advances & Concepts in Cervical Cancer Trials (GCIG report) -IJGC

Closed trials: (3 minutes)

1) EORTC 55994: NAC + RH vs CCRT

Ottevanger

CURRENT ACTIVE RANDOMIZED TRIALS WITH GCIG PARTICIPATION:

(3-5 minutes each)

Surgery plus Radiation +/- CT

2) Post-Op RT

a. KGOG 0801/GOG 263 (RTOG): RT vs CCRT (intermed.risk post op) Ryu

b. RTOG 0724 (GOG): ChemoRT +/- CT (high risk post op) Small

3) Para-aortic Lymphadenectomy

a. G-GOC LiLACS

Lu

Chemoradiation

4) TACO KGOG-Thai (**CCRN**) (RTOG, GICOM, VietNam, + ?)

Ryu

5) OUTBACK ANZGOG (**CCRN**) (GOG, RTOG, + ?)

Mileschkin

6) INTERLACE MRC-NCRI (**CCRN**) (GICOM, MaNGO, + ??)

McCormack

7) TIME-C RTOG

Small

Minimal Invasive Surgery	
8) SHAPE NCIC CTG (CCRN) (DGOG, + ?)	Plante
9) ConCerv G-GOC	Lu
10)LACC G-GOC	Lu
11)GOG 0278	Miller
Chemo (Bev.)	
12)GOG 1 st line mets (+/vs Bev.)	Miller
Immunotherapy	
13)GOG high risk maintainance (ADXS-HPV)	Miller
Vulvar Cancer	
14)GROINSS-V II DGOG (EORTC, GOG)	Bekkers
15)GOG 0279	Miller

NEW/PROPOSED OR DEVELOPING CONCEPTS :

1) RTOG Hypofractionation	Small/Gaffney
2) NCIC-CTG Neo-adj. CT & fertility sparing surgery (stage IBI)	Plante
3) GINECO Sentinel lymph node biopsy	Lecuru/Plante
a. Survey status	Keller/Sehouli
4) EORTC-GCG Transgene + anti-PD-1 antibody	Ottevanger for Scholl
5) EORTC-GCG 1411CCRT (Phase II/III VGX-3100 and INO-9012)	Ottevanger

ANNOUNCEMENT: GCIG CCRN Cx Ca Education Symposium, Jan. 2016, Bangkok

DISCUSSION

ADJOURN